| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 19 | 2023 | 275 | 2.870 |
Why?
|
| Mesencephalon | 9 | 2020 | 49 | 2.520 |
Why?
|
| Action Potentials | 12 | 2020 | 246 | 2.140 |
Why?
|
| Neurons | 19 | 2019 | 1263 | 2.060 |
Why?
|
| Substantia Nigra | 8 | 2017 | 52 | 1.550 |
Why?
|
| Ventral Tegmental Area | 9 | 2023 | 49 | 1.320 |
Why?
|
| Cocaine | 6 | 2019 | 251 | 1.220 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2017 | 83 | 1.050 |
Why?
|
| Neural Inhibition | 5 | 2019 | 48 | 0.920 |
Why?
|
| Patch-Clamp Techniques | 10 | 2020 | 228 | 0.920 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 6 | 2018 | 135 | 0.770 |
Why?
|
| Norepinephrine | 5 | 2014 | 97 | 0.770 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 3 | 2015 | 13 | 0.710 |
Why?
|
| Animals | 39 | 2024 | 16992 | 0.690 |
Why?
|
| Nucleus Accumbens | 5 | 2019 | 100 | 0.650 |
Why?
|
| Electrophysiological Phenomena | 3 | 2014 | 20 | 0.600 |
Why?
|
| Choice Behavior | 1 | 2019 | 93 | 0.560 |
Why?
|
| Avoidance Learning | 1 | 2019 | 70 | 0.560 |
Why?
|
| Glycine | 1 | 2018 | 47 | 0.550 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2017 | 12 | 0.530 |
Why?
|
| Endocannabinoids | 2 | 2023 | 41 | 0.530 |
Why?
|
| Astrocytes | 1 | 2019 | 244 | 0.510 |
Why?
|
| Long-Term Potentiation | 1 | 2017 | 109 | 0.510 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2016 | 38 | 0.480 |
Why?
|
| Electrophysiology | 4 | 2012 | 138 | 0.470 |
Why?
|
| GABA Antagonists | 5 | 2010 | 29 | 0.450 |
Why?
|
| Synapses | 2 | 2019 | 185 | 0.450 |
Why?
|
| Neuronal Plasticity | 2 | 2017 | 126 | 0.440 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2015 | 1766 | 0.440 |
Why?
|
| Receptors, Metabotropic Glutamate | 3 | 2004 | 26 | 0.430 |
Why?
|
| Glutamic Acid | 3 | 2019 | 131 | 0.430 |
Why?
|
| Biological Clocks | 4 | 2012 | 52 | 0.430 |
Why?
|
| Mice | 13 | 2024 | 6644 | 0.400 |
Why?
|
| Motor Activity | 2 | 2019 | 437 | 0.400 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2018 | 81 | 0.400 |
Why?
|
| Behavior, Animal | 2 | 2014 | 373 | 0.370 |
Why?
|
| Rats | 13 | 2011 | 3735 | 0.360 |
Why?
|
| Brain | 3 | 2016 | 1472 | 0.340 |
Why?
|
| Reward | 4 | 2023 | 112 | 0.340 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2024 | 47 | 0.330 |
Why?
|
| Receptors, GABA | 1 | 2010 | 28 | 0.320 |
Why?
|
| Male | 22 | 2020 | 23409 | 0.310 |
Why?
|
| Receptors, Dopamine D2 | 4 | 2019 | 83 | 0.300 |
Why?
|
| Receptors, GABA-A | 4 | 2010 | 65 | 0.290 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2014 | 9 | 0.290 |
Why?
|
| GABA Agonists | 3 | 2010 | 21 | 0.270 |
Why?
|
| Locus Coeruleus | 1 | 2006 | 17 | 0.260 |
Why?
|
| Receptors, AMPA | 3 | 2017 | 58 | 0.260 |
Why?
|
| Receptors, Glutamate | 2 | 2018 | 28 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 694 | 0.240 |
Why?
|
| Isonicotinic Acids | 2 | 2010 | 7 | 0.240 |
Why?
|
| Mice, Knockout | 6 | 2024 | 1035 | 0.230 |
Why?
|
| Female | 15 | 2022 | 24698 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 1869 | 0.230 |
Why?
|
| Mucopolysaccharidoses | 1 | 2024 | 3 | 0.220 |
Why?
|
| Amphetamine | 2 | 2003 | 21 | 0.220 |
Why?
|
| Synaptic Transmission | 2 | 2006 | 149 | 0.220 |
Why?
|
| Glycosaminoglycans | 1 | 2024 | 24 | 0.220 |
Why?
|
| Antipsychotic Agents | 2 | 2012 | 80 | 0.200 |
Why?
|
| Receptors, GABA-B | 4 | 2010 | 11 | 0.190 |
Why?
|
| Globus Pallidus | 3 | 1999 | 21 | 0.190 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 26 | 0.190 |
Why?
|
| Milk | 1 | 2022 | 56 | 0.190 |
Why?
|
| Embryonic and Fetal Development | 1 | 2002 | 32 | 0.190 |
Why?
|
| Pregnancy, Animal | 1 | 2002 | 14 | 0.190 |
Why?
|
| Microglia | 1 | 2024 | 208 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 3 | 2012 | 125 | 0.190 |
Why?
|
| Cats | 1 | 2002 | 82 | 0.180 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2002 | 40 | 0.180 |
Why?
|
| Schizophrenia | 2 | 2012 | 93 | 0.180 |
Why?
|
| Thiazoles | 1 | 2012 | 76 | 0.180 |
Why?
|
| Potassium Channels | 4 | 2010 | 80 | 0.180 |
Why?
|
| Bluetongue | 3 | 2012 | 11 | 0.180 |
Why?
|
| Piperazines | 1 | 2012 | 120 | 0.170 |
Why?
|
| Bluetongue virus | 2 | 2012 | 11 | 0.170 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 20 | 0.170 |
Why?
|
| Electrodes, Implanted | 1 | 2020 | 22 | 0.170 |
Why?
|
| Membrane Transport Proteins | 1 | 2001 | 100 | 0.160 |
Why?
|
| Models, Neurological | 2 | 2012 | 136 | 0.160 |
Why?
|
| Picrotoxin | 3 | 2010 | 14 | 0.160 |
Why?
|
| Piperidines | 2 | 2019 | 83 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 224 | 0.150 |
Why?
|
| Algorithms | 3 | 2012 | 509 | 0.150 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2019 | 8 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 1999 | 92 | 0.150 |
Why?
|
| Steroid 12-alpha-Hydroxylase | 1 | 2018 | 2 | 0.150 |
Why?
|
| Organ Culture Techniques | 2 | 2011 | 101 | 0.150 |
Why?
|
| Computer Simulation | 2 | 2012 | 408 | 0.150 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 1596 | 0.140 |
Why?
|
| Steroids | 1 | 2018 | 45 | 0.140 |
Why?
|
| Benzamides | 1 | 2019 | 81 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 386 | 0.140 |
Why?
|
| Serotonin | 1 | 2019 | 123 | 0.140 |
Why?
|
| Pedunculopontine Tegmental Nucleus | 1 | 2017 | 1 | 0.140 |
Why?
|
| Pyridines | 1 | 2019 | 139 | 0.140 |
Why?
|
| Raphe Nuclei | 1 | 2017 | 6 | 0.140 |
Why?
|
| Locomotion | 2 | 2019 | 105 | 0.140 |
Why?
|
| Fetus | 2 | 2012 | 101 | 0.140 |
Why?
|
| Subthalamic Nucleus | 1 | 2017 | 15 | 0.140 |
Why?
|
| Neurons, Afferent | 1 | 2017 | 44 | 0.140 |
Why?
|
| Corpus Striatum | 1 | 1999 | 121 | 0.140 |
Why?
|
| Time Factors | 3 | 2011 | 1857 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 180 | 0.130 |
Why?
|
| Cattle Diseases | 2 | 2009 | 30 | 0.130 |
Why?
|
| Oxygen | 1 | 2018 | 218 | 0.130 |
Why?
|
| Indoles | 1 | 2019 | 187 | 0.130 |
Why?
|
| Cyclic GMP | 1 | 2017 | 53 | 0.130 |
Why?
|
| Electric Stimulation | 4 | 2013 | 186 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 252 | 0.130 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2006 | 32 | 0.120 |
Why?
|
| Models, Biological | 1 | 2019 | 712 | 0.120 |
Why?
|
| Microelectrodes | 1 | 2015 | 22 | 0.110 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2015 | 7 | 0.110 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 36 | 0.110 |
Why?
|
| Dopamine Agents | 2 | 2013 | 28 | 0.110 |
Why?
|
| Arrestins | 1 | 2014 | 28 | 0.110 |
Why?
|
| Iontophoresis | 2 | 2013 | 10 | 0.110 |
Why?
|
| Hemoglobinopathies | 1 | 2014 | 5 | 0.110 |
Why?
|
| Food Deprivation | 1 | 2013 | 33 | 0.100 |
Why?
|
| Immunoglobulin D | 1 | 2013 | 5 | 0.100 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2013 | 2 | 0.100 |
Why?
|
| Abortion, Veterinary | 1 | 2012 | 3 | 0.100 |
Why?
|
| Normal Distribution | 1 | 2012 | 14 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cattle | 4 | 2022 | 498 | 0.090 |
Why?
|
| Bicuculline | 4 | 1999 | 18 | 0.090 |
Why?
|
| Viral Vaccines | 1 | 2012 | 37 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2012 | 74 | 0.090 |
Why?
|
| Rats, Wistar | 2 | 2004 | 283 | 0.090 |
Why?
|
| Calcium Signaling | 2 | 2004 | 107 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 749 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1271 | 0.090 |
Why?
|
| Baclofen | 3 | 1999 | 9 | 0.080 |
Why?
|
| Evoked Potentials | 2 | 2010 | 91 | 0.080 |
Why?
|
| Obesity | 1 | 2018 | 1151 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2011 | 352 | 0.080 |
Why?
|
| Calcium | 2 | 2004 | 491 | 0.080 |
Why?
|
| Aspartic Acid | 2 | 2013 | 51 | 0.080 |
Why?
|
| Phosphinic Acids | 2 | 1999 | 3 | 0.080 |
Why?
|
| Propanolamines | 2 | 1999 | 13 | 0.080 |
Why?
|
| Quinpirole | 2 | 2014 | 18 | 0.080 |
Why?
|
| Dopamine Agonists | 2 | 2014 | 34 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 432 | 0.070 |
Why?
|
| Humans | 11 | 2024 | 43102 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1124 | 0.070 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2007 | 5 | 0.070 |
Why?
|
| Learning | 1 | 2009 | 161 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2024 | 638 | 0.070 |
Why?
|
| Autoreceptors | 1 | 2006 | 2 | 0.060 |
Why?
|
| Enkephalin, Methionine | 1 | 2006 | 6 | 0.060 |
Why?
|
| Quinoxalines | 1 | 2006 | 16 | 0.060 |
Why?
|
| Bacterial Proteins | 2 | 2022 | 595 | 0.060 |
Why?
|
| Receptors, Dopamine D3 | 2 | 2019 | 17 | 0.060 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2006 | 39 | 0.060 |
Why?
|
| Goat Diseases | 1 | 2005 | 6 | 0.060 |
Why?
|
| Geographic Information Systems | 1 | 2005 | 47 | 0.060 |
Why?
|
| Sheep | 3 | 2012 | 77 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2022 | 245 | 0.050 |
Why?
|
| Ryanodine | 1 | 2004 | 4 | 0.050 |
Why?
|
| Apamin | 1 | 2004 | 8 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 26 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2004 | 34 | 0.050 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2004 | 43 | 0.050 |
Why?
|
| Dopamine Antagonists | 2 | 2019 | 48 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2024 | 39 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2004 | 39 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2004 | 75 | 0.050 |
Why?
|
| Caffeine | 1 | 2004 | 28 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 44 | 0.050 |
Why?
|
| Membrane Potentials | 2 | 2007 | 222 | 0.050 |
Why?
|
| Lysosomes | 1 | 2024 | 86 | 0.050 |
Why?
|
| Self Administration | 1 | 2004 | 69 | 0.050 |
Why?
|
| Potassium | 1 | 2004 | 109 | 0.050 |
Why?
|
| Conditioning, Operant | 1 | 2004 | 90 | 0.050 |
Why?
|
| Cocaine-Related Disorders | 1 | 2004 | 102 | 0.050 |
Why?
|
| Amphetamines | 1 | 2003 | 5 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 3 | 0.050 |
Why?
|
| Aminoglycosides | 1 | 2022 | 6 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 8 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2022 | 9 | 0.050 |
Why?
|
| Levodopa | 1 | 2003 | 26 | 0.050 |
Why?
|
| beta-Lactamases | 1 | 2022 | 34 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 247 | 0.050 |
Why?
|
| Extraembryonic Membranes | 1 | 2002 | 6 | 0.050 |
Why?
|
| Pregnancy | 2 | 2012 | 1772 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2012 | 15 | 0.050 |
Why?
|
| Afferent Pathways | 2 | 1999 | 43 | 0.050 |
Why?
|
| Uterus | 1 | 2002 | 52 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 211 | 0.050 |
Why?
|
| Patient Preference | 1 | 2012 | 60 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2002 | 157 | 0.040 |
Why?
|
| Carbon-Oxygen Ligases | 1 | 2001 | 1 | 0.040 |
Why?
|
| Enterococcus | 1 | 2001 | 8 | 0.040 |
Why?
|
| Placenta | 1 | 2002 | 117 | 0.040 |
Why?
|
| Serotyping | 2 | 2012 | 37 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 282 | 0.040 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2001 | 59 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2003 | 403 | 0.040 |
Why?
|
| Kinetics | 2 | 1999 | 695 | 0.040 |
Why?
|
| Italy | 2 | 2012 | 27 | 0.040 |
Why?
|
| Goats | 2 | 2012 | 23 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1999 | 20 | 0.040 |
Why?
|
| Electric Impedance | 1 | 1999 | 28 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 1999 | 55 | 0.040 |
Why?
|
| Pyridazines | 1 | 1999 | 16 | 0.040 |
Why?
|
| Receptors, Presynaptic | 1 | 1999 | 4 | 0.040 |
Why?
|
| Amino Acid Transport Systems, Acidic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 455 | 0.040 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2019 | 46 | 0.040 |
Why?
|
| Morphine | 1 | 2019 | 69 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2001 | 321 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 150 | 0.040 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 1998 | 6 | 0.040 |
Why?
|
| Nerve Degeneration | 1 | 1999 | 111 | 0.040 |
Why?
|
| Fluoxetine | 1 | 1998 | 15 | 0.040 |
Why?
|
| Disease Outbreaks | 2 | 2012 | 175 | 0.030 |
Why?
|
| Axons | 1 | 2019 | 117 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1998 | 86 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1998 | 102 | 0.030 |
Why?
|
| Prevalence | 2 | 2014 | 1612 | 0.030 |
Why?
|
| Papio | 1 | 2016 | 22 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 1001 | 0.030 |
Why?
|
| Middle Aged | 4 | 2013 | 12222 | 0.030 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1996 | 12 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 151 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 152 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2014 | 3 | 0.030 |
Why?
|
| Benzenesulfonates | 1 | 2014 | 9 | 0.030 |
Why?
|
| Chromogranins | 1 | 2014 | 5 | 0.030 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2014 | 5 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 934 | 0.030 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2013 | 6 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 113 | 0.030 |
Why?
|
| Biophysics | 1 | 2013 | 38 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 73 | 0.030 |
Why?
|
| Buffaloes | 1 | 2012 | 3 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2012 | 9 | 0.020 |
Why?
|
| South Africa | 1 | 2012 | 38 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 341 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2012 | 75 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 575 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 204 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 158 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 13872 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2010 | 82 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2010 | 73 | 0.020 |
Why?
|
| Croatia | 1 | 2009 | 4 | 0.020 |
Why?
|
| Behavior | 1 | 2009 | 35 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2009 | 57 | 0.020 |
Why?
|
| Drinking | 1 | 2009 | 37 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 1177 | 0.020 |
Why?
|
| Maze Learning | 1 | 2009 | 113 | 0.020 |
Why?
|
| Muscimol | 2 | 1999 | 16 | 0.020 |
Why?
|
| Barium Compounds | 1 | 2007 | 2 | 0.020 |
Why?
|
| Prazosin | 1 | 2007 | 9 | 0.020 |
Why?
|
| Salicylamides | 1 | 2007 | 13 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2007 | 17 | 0.020 |
Why?
|
| Yohimbine | 1 | 2007 | 24 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2007 | 29 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 611 | 0.020 |
Why?
|
| Chlorides | 1 | 2007 | 59 | 0.020 |
Why?
|
| Attention | 1 | 2009 | 174 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2009 | 306 | 0.020 |
Why?
|
| Fear | 1 | 2009 | 272 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2005 | 11 | 0.010 |
Why?
|
| Sentinel Surveillance | 1 | 2005 | 25 | 0.010 |
Why?
|
| Animals, Wild | 1 | 2005 | 24 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2012 | 2544 | 0.010 |
Why?
|
| Indans | 1 | 2004 | 14 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 236 | 0.010 |
Why?
|
| Teicoplanin | 1 | 2001 | 3 | 0.010 |
Why?
|
| Vancomycin Resistance | 1 | 2001 | 2 | 0.010 |
Why?
|
| Vancomycin | 1 | 2001 | 7 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2001 | 27 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2001 | 26 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2001 | 25 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 96 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 1621 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 1998 | 27 | 0.010 |
Why?
|
| Aged | 2 | 2004 | 8214 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 2853 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1998 | 112 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1996 | 587 | 0.010 |
Why?
|